It was already proposed that targeting the NO/sGC/cGMP pathway can attenuate chemotherapy-induced cardiotoxicity and even potentially reduce the occurrence of secondary malignant tumours that might develop after DOXO-treatment [84]. This evidence concerns the gene SGCB and cancer.